In ophthalmology trials, dropout is often treated like an unfortunate reality. In practice, it is usually more predictable than teams assume and more preventable than protocols reflect.
Read More
In clinical trials that deal with ocular hypertension, intraocular pressure (IOP) is not just a measurement. It is often the primary determinant of regulatory credibility and treatment response...
Read More
Selecting an ophthalmology CRO is fundamentally a risk decision. Sponsors and clinical operations leaders are not just choosing a vendor; they are choosing how ocular endpoints will be protected...
Read More
Ophthalmology Clinical Trials: Strategic Growth, Scientific Innovation, and Execution Risk for Sponsors Key Takeaways Aging populations and chronic disease growth are expanding the patient pool for...
Read More
Patient Centric Clinical Trials: Reducing Transportation Risk to Protect Timelines and Data Integrity Key Takeaways Transportation barriers are not just patient experience issues, they are protocol...
Read More
How to Reduce Patient Dropout Rates in Clinical Trials: Sponsor-Driven Retention Strategies That Protect Timelines Key Takeaways Dropout is a sponsor risk that impacts timelines, data continuity,...
Read More
How Small Operational Gaps Create Big Endpoint Risk in BCVA, OCT, and IOP Testing Key Takeaways BCVA, OCT, and IOP endpoints drift when setup, technique, timing, and documentation are not controlled...
Read More